The Inflation Reduction Act's drug price controls may be popular. But by discouraging companies from investing in innovative, accessible drugs, they'll harm current and future patients in need of effective therapies.
Subscribe to:
Post Comments (Atom)
< + > Weekly Roundup – June 27, 2026
Welcome to our Healthcare IT Today Weekly Roundup . Each week, we’ll be providing a look back at the articles we posted and why they’re impo...
-
As I’m sure you know, times are tough. Wages have largely remained the same while prices have risen across the board – and healthcare is no ...
-
Solution Erases Long Phone Holds for Patients, Supports Overwhelmed Medical Front Desk Workers, and Improves Patient Access to Physicians A...
-
Announcement written by Zack Kanter, Founder and CEO at Stedi In February of last year, I gathered our engineering team in a war room. Chan...
No comments:
Post a Comment